What to know about CuATSM clinical trials
Sep 18, 2019•11 min•Season 1Ep. 16
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode, Dr. Fernando Vieira, CSO at the ALS Therapy Development Institute (ALS TDI), joins us to discuss Copper ATSM (CuATSM)clinical trials. CuATSM is a small molecule drug sponsored by the company Collaborative MedicinalDevelopment (CMD). They recently completed enrollment of a small, Phase 1 clinical trial in Australia.
You can access all episodes of the Endpoints Podcast for free by visiting www.als.net/endpoints and registering.
Support the show: https://www.als.net/donate/
See omnystudio.com/listener for privacy information.
For the best experience, listen in Metacast app for iOS or Android